This cohort study assesses the association of tumor necrosis factor inhibitors, non–tumor necrosis factor inhibitor drugs, and Janus kinase inhibitors with incident cancer risk among patients with rheumatoid arthritis. Here, TNF is linked to rheumatoid arthritis.